<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-99767</identifier>
<setSpec>1130-1406</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Antifungal treatment options in the critically ill patient</dc:title>
<dc:description xml:lang="en">Invasive fungal infections, especially in the critical care setting, have become an excellent target for prophylactic, empiric, and pre-emptive therapy interventions due to their associated high morbidity, mortality rate, increased incidence, and healthcare costs. For these reasons, new studies and laboratory tests have been developed over the last few years in order to formulate an early therapeutic intervention strategy in an attempt to reduce the high mortality rate associated with these infections. In recent years, evidencebased studies have shown the roles that the new antifungal drugs play in the treatment of invasive mycosis in seriously ill and complex patients, although data from critically ill patients are more limited. New antifungal agents have been analyzed in different clinical situations in critical care units, and the increasing number of non-Candida albicans species suggest that the application of early echinocandin therapy in critically ill patients with invasive candidiasis is a good option. Voriconazole should be recommended for invasive aspergillosis as a first line option(AU)</dc:description>
<dc:creator>Pemán, Javier</dc:creator>
<dc:creator>Zaragoza, Rafael</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Debido a sus tasas altas de morbimortalidad y a los elevados costes sanitarios asociados, las infecciones fúngicas invasivas en el paciente crítico son un adecuado objetivo para el desarrollo de estrategias terapéuticas, tanto profilácticas, como empíricas o anticipadas. Para intentar disminuir su elevada mortalidad, se han desarrollado nuevas técnicas de laboratorio que ayudan a la instauración temprana del tratamiento. En los últimos años se ha evaluado el papel de los nuevos antifúngicos en este contexto, aunque son escasos los estudios que incluyen a pacientes críticos. La mayoría de las guías y las recomendaciones publicadas respaldan la estrategia de desescalada terapéutica, especialmente en el paciente con inestabilidad hemodinámica, aconsejando el uso de equinocandinas como primera opción en la candidiasis invasiva y de voriconazol para el tratamiento de la aspergilosis invasiva(AU)</dc:description>
<dc:source>Rev Iberoam Micol;29(2): 108-113, abr.-jun. 2012. tab, ilus</dc:source>
<dc:identifier>ibc-99767</dc:identifier>
<dc:title xml:lang="es">Opciones terapéuticas para el tratamiento antifúngico en el paciente crítico</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d53933^s22057</dc:subject>
<dc:subject>^d28418</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d943^s22073</dc:subject>
<dc:subject>^d52786^s22073</dc:subject>
<dc:subject>^d14625^s22073</dc:subject>
<dc:subject>^d1414^s22073</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d3439^s22045</dc:subject>
<dc:subject>^d11525^s22073</dc:subject>
<dc:subject>^d27953^s22073</dc:subject>
<dc:subject>^d31378^s22073</dc:subject>
<dc:subject>^d32031^s22057</dc:subject>
<dc:subject>^d13150^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>201206</dc:date>
</metadata>
</record>
</ibecs-document>
